Vir, GSK's experimental COVID-19 treatment moves into a Phase 3 clinical trial
-3.32% gained 1.3% in premarket trading on Friday, the day after the biotech and GlaxoSmithKline GSK, +0.36% said they started dosing patients in a late-stage clinical trial for an experimental antibody-based COVID-19 treatment. The Phase 3 study is part of the National Institutes of Health's Accelerating COVID-19 Therapeutic Interventions and Vaccines Program. The companies are testing VIR-7831 in patients who have been hospitalized due to COVID-19 infections. The investigational treatment "has the potential to neutralize the virus and kill infected cells, [which] coul...
Source: marketwatch.com